Oversold

BIOX

Same as last week
Valuation50/ 100
Cash flow & growth38/ 100
Upside potential43/ 100
Risk potential51/ 100

BIOX's valuation appears fair, below average fundamentals limit its appeal, while forward estimates point to a return to profit and improving margins, though analyst coverage is limited.

Valuation

Valuation stays neutral because earnings are difficult to compare across periods. Business trends, outlook and financial risk still contribute to the overall score.

Cash flow & growth

Business trends are weak. Over the past year: revenue -29.8%, operating margin -7 percentage points. The business score is 37.9/100. Growth, margins and cash generation drive the score. Missing or older data receives less weight.

Favorable scenario

Weaker business results limit upside support. Price history provides the reference because earnings are difficult to compare.

The calculation starts with the stock’s typical weekly price movements, adjusted for business performance and outlook. Unusually large jumps have less influence. The result is 38.3% upside, or about $0.59.

This is a scenario based on our model, not a forecast or probability.

Downside scenario

The 50.5% downside is driven by operating stress: the model assumes earnings fall 34.3% and the PE falls 24.6%. That gives $0.00 per share at a 85.1× PE, or about $0.21. Price swings alone suggest 50.1% downside.

This is a scenario based on our model, not a forecast or probability.

BIOX vs Historical averages

MetricCurrentAverageRelative
PE113x131x14% lower
PE percentile50500% lower
EPS-$3.89-$0.23$3.66 lower
FCF$72.2M-$3.5M+$75.7M
Loading historical comparisons…

BIOX’s earnings are below their historical averages, while its earnings multiple is lower.

BIOX Forward outlook

MetricOutlook
Forward valuation--
Forward earningsTurning positive
Forward revenueStrong growth
Forward profitabilityStrongly expanding
Analyst coverageLimited
Estimate dispersionTight

BIOX’s outlook is generally improving, supported by an expected return to profitability.

BIOX PE Valuation

Loading pe valuation table…

This table applies BIOX's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.

BIOX Earnings Per Share

Loading earnings per share…

This chart tracks BIOX's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.

BIOX Quarterly Revenue

Loading quarterly revenue…

This chart tracks BIOX's quarterly revenue over time and shows how sales are changing from year to year.

BIOX Free Cash Flow

Loading free cash flow…

This chart tracks BIOX's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.

BIOX Total Shares

Loading shares over time…

This chart tracks changes in BIOX's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.

BIOX Net Leverage

Loading net leverage…

Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.

BIOX PE vs Basic Materials Sector

Loading pe vs sector average…

This chart compares BIOX's price-to-earnings (PE) ratio with the Basic Materials sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.

BIOX Weekly Price

Loading weekly price…

This chart uses BIOX's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.

BIOX Weekly Moving Averages

Loading weekly moving averages…

This chart compares BIOX's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.

BIOX Yearly ROI

Loading yearly ROI…

Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.